Odomzo

Country: New Zealand

Language: English

Source: Medsafe (Medicines Safety Authority)

Active ingredient:

Sonidegib phosphate 280.8mg equivalent to sonidegib 200mg

Available from:

CARSL Consulting

Dosage:

200 mg

Pharmaceutical form:

Capsule

Composition:

Active: Sonidegib phosphate 280.8mg equivalent to sonidegib 200mg Excipient: Colloidal silicon dioxide Crospovidone Gelatin Iron oxide red Lactose monohydrate Magnesium stearate Opacode black S-1-277002 Poloxamer 188 Purified water Sodium laurilsulfate Titanium dioxide

Prescription type:

Prescription

Therapeutic indications:

Odomzo is indicated for the treatment of adult patients with: - Locally advanced basal cell carcinoma (BCC) who are not amenable to curative surgery or radiation therapy. - Metastatic BCC.

Product summary:

Package - Contents - Shelf Life: Bottle, plastic, HDPE with CR cap and 1g desiccant - 30 capsules - 48 months from date of manufacture stored at or below 25°C protect from moisture

Authorization date:

2018-03-09